INTRODUCTION {#s1}
============

Liver transplantation is an effective and promising choice to cure patients with end-stage liver diseases or early inoperable hepatocellular carcinoma (HCC) \[[@R1]\], who otherwise have less than one year to live \[[@R2]\]. Advances in surgical techniques and medical care have lately yielded a one-year survival rate after liver transplantation of more than 80%-90% \[[@R3], [@R4]\]. However, liver transplant recipients (LTRs) still have a lower probability of long-term survival than the age-matched general population \[[@R5]\]. Closely followed by common causes of death in the general population, hepatic-related, post-transplant malignancies account for 22% of LTR mortality \[[@R6]\]. Several epidemiological studies have revealed a 2- to 4-fold higher risk of post-transplant *de novo* malignancies in LTRs than in the general population \[[@R5], [@R7]--[@R9]\]. Immunosuppression is an essential contributor to oncogenesis in LTRs, particularly for those with infection-related cancers. This viewpoint was firmly supported by the similar spectrum of cancer risk seen in LTRs and patients with acquired immunodeficiency syndrome (AIDS) \[[@R10]\].

Malignancies occurring after solid organ transplantations, other than liver, are mainly *de novo* cancers because recipients with active malignancies are typically excluded. Recipients with HCC typically have poor survival and considerably elevated recurrence rates because of poor patient selection \[[@R13], [@R14]\]. The Milan criteria have been widely used for candidate selection since 1996, and five-year survival obtained using these criteria was more satisfactory than that obtained using others (87% *vs*. 62%) \[[@R15]\]. In Taiwan, the first liver transplantation for HCC was performed in 1999. Because transplantation for HCC has since become well accepted in Taiwan, recurrent malignancies among LTRs could become an increasingly serious problem.

Few studies have summarized and compared *de novo* and recurrent malignancies after liver transplantation. Of these, many were limited by a single-center design or small cohort population and they rarely analyzed risk factors associated with post-transplant malignancies in LTRs \[[@R9], [@R11], [@R12], [@R16]\]. Determining risk factors for post-transplant malignancies provides a basis for preventive and therapeutic interventions and could promote early diagnosis and improve long-term survival. The present study aimed to retrospectively determine the patterns of post-transplant malignancies and associated risk factors. The spectrum and prevalence of post-transplant malignancies vary among ethnicities and geographical regions. We herein analyzed the incidence of *de novo* and recurrent malignancies in Taiwanese LTRs over a 14.5-year observation period compared to the general population. As per our review of relevant data, our study is the first to provide insights into cancer etiology and support the development of evidence-based strategies for identifying high-risk recipients by examining patients of Chinese ethnicity.

MATERIALS AND METHODS {#s2}
=====================

Data source {#s2_1}
-----------

This population-based cohort study retrospectively analyzed data from Taiwan\'s National Health Insurance Research database (NHIRD). It enrolled more than 99.9% of the entire population of 23.32 million Taiwanese residents, and the Bureau of National Health Insurance (NHI) is affiliated to more than 93% medical institutions in Taiwan. The claims data retrieved from the NHIRD were computerized and de-identified. The NHIRD comprises enrollment information, inpatient and outpatient claims for reimbursement, and prescription drugs and procedures. Furthermore, the database provides disease diagnostic codes according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). In addition, the annual incidence rate of cancer in the general population was obtained from the Taiwan National Cancer Registry ([http://www.hpa.gov.tw/BHPNet/Web /Stat/StatisticsShow.aspx?No = 200911300001](http://www.hpa.gov.tw/BHPNet/Web%20/Stat/StatisticsShow.aspx?No%20=%20200911300001), and [http://www.hpa.gov.tw/BHPNet/ Web/ Stat /Statistics.aspx](http://www.hpa.gov.tw/BHPNet/%20Web/%20Stat%20/Statistics.aspx)).

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in *a priori* approval by the Institutional Review Board of Chang Gung Memorial Hospital (Registration number: IRB 103-0102B) and NHIRD research committee (Registration number: NHIRD-103-103). Personal information and medical records were identified and anonymized; therefore, informed consent from the LTRs was unavailable.

Definition and selection of the study population {#s2_2}
------------------------------------------------

The target LTRs were identified on the basis of the ICD-9-CM code 996.82 or V427 from the catastrophic illness database. In addition, we excluded patients who did not match the operation code of liver transplant surgery (505, 75020A, or 75020B) within this period. Finally, 2938 LTRs were included in this cohort study.

Preoperative comorbidities were identified using a preset definition of at least one recorded inpatient department diagnosis or five recorded outpatient department diagnoses before transplantation using the claimed codes. The specific ICD-9-CM codes for identification are as follows: liver cirrhosis (ICD-9-CM 571.2, 571.5, and 571.6), chronic hepatitis (ICD-9-CM 070, 571, and 573.3), alcoholic hepatitis (ICD-9-CM 571.2 and 571.3), hepatitis B (ICD-9-CM 070.2, 070.3, V0261, and V0269), hepatitis C (ICD-9-CM 070.41, 070.44, 070.51, 070.54, 070.7, and V262), hypertension (ICD-9-CM 401-405), diabetes mellitus (ICD-9-CM 250), peptic ulcer (ICD-9-CM 531-533), obesity (ICD-9-CM 278), ascites (ICD-9-CM 789.5), hepatic coma (ICD-9-CM 070.0, 070.2, 070.4, 070.6, 70.2, 70.41, 572.2, 070.71, and 348.3), renal failure (ICD-9-CM 584-586), pulmonary disease (ICD-9-CM 490-496), hypercholesterolemia (ICD-9-CM 272), malignancies (ICD-9-CM 140-208.91), biliary atresia (ICD-9-CM 751.61), Wilson disease (ICD-9-CM 275.1 and E8301), glycogen storage disease (ICD-9-CM 271.0), urea cycle metabolism disorders (ICD-9-CM 270.6), bacteremia (ICD-9-CM 038 and 998.5), and postoperative bleeding (ICD-9-CM 998.0-998.2). Death was defined as the matched death code or termination from the NHI program.

Definition of primary outcome {#s2_3}
-----------------------------

The primary outcomes were post-transplant malignancies and long-term mortality in the LTRs. Post-transplant cancers were defined according to the recorded ICD-9-CM codes 140-208.91 in the same catastrophic illness database after liver transplantation. Benign neoplasms (ICD-9-CM 210-229) and *in situ* carcinoma (ICD-9-CM 230-234) were not included as post-transplant malignancies. To avoid bias in the post-transplant malignancy rate, which may be caused by an increased pre-transplantation examination, patients diagnosed with cancer within 3 months postoperatively were excluded. Furthermore, *de novo* cancer is defined as the first occurrence without a prior existence of that cancer in the body. Recurrent malignancy is defined as cancer reappearance after a remission interval when the cancer cannot be detected. The relapsed cancer can develop at the original location or in other parts of the body. Variables comprised demographic characteristics, and comorbidities were analyzed for the risk factors for post-transplant malignancies.

The survival time of the LTRs was defined as the number of days from transplantation to death. For comparison of long-term survival LTRs were categorized into four groups: 1. Malignancy-free group, no cancer diagnosed throughout the study period; 2. Malignancy-cured group, preoperative malignancies were not diagnosed postoperatively. 3. De novo group, the first occurrence of cancer postoperatively; and 4. Recurrent group, the postoperative development of relapsed cancer, which existed preoperatively.

Statistical analysis {#s2_4}
--------------------

Data are expressed as means ± standard deviation, except the representatives of the survival time that are presented as mean ± standard error (SE). Statistical analysis was performed using SAS (version 9.3; SAS Institute Inc., Cary, NC, USA). The variables for comparing the risk factors between the malignancy and non-malignancy groups were expressed as competing risk cox regression model with control mortality. Patient death or loss to follow-up in the NHIRD was identified as patient mortality. A *p*-value of \< 0.05 was considered significant, and all statistical analyses were two-sided.

RESULTS {#s3}
=======

Characteristics of the LTRs {#s3_1}
---------------------------

We recruited 2938 Taiwanese LTRs who underwent transplantation between July 1998 and December 2012; patient characteristics are described in Table [1](#T1){ref-type="table"}. Of all LTRs, 2068 were males, and 870 were females; 341 were pediatric patients less than 18 years old. The average age at the time of the transplant was 46.42 ± 17.68 years (range, 4.44 months to 75.15 years; median, 51.76 years). The average follow-up interval was 3.79 ± 3.26 years, with a total follow-up of 14176 person-years. The most common follow-up duration was between 1 and 5 years, and 6.19% of the LTRs were followed for more than 10 years. Furthermore, 1440 LTRs were diagnosed with preoperative malignancies, 1313 of these with liver cancer (91.18%). The other 1498 LTRs were cancer-free preoperatively. 2484 patients had liver cirrhosis. Among the 2761 cases of chronic hepatitis, 1416 were HBV related, 662 were HCV related, and 565 were alcohol related.

###### Characteristics of Taiwan liver transplant recipients from 1998 through 2012

  N=2938                                                           N, Mean   %, SD
  ---------------------------------------------------------------- --------- -------
  **Sex**                                                                    
   Male                                                            2068      70.39
   Female                                                          870       29.61
  **Age (years)**[^†^](#tfn_001){ref-type="table-fn"}              46        17.68
  **Age group**                                                              
   \< 18                                                           341       11.61
   ≧ 18                                                            2597      88.39
  **Follow-up time (years)**[^†^](#tfn_001){ref-type="table-fn"}   3.79      3.26
   \<1                                                             623       21.20
   1-5                                                             1466      49.90
   5-10                                                            667       22.70
   \>10                                                            182       6.19
  **Person-years of follow-up**                                    14176     
  **Pre-op cancer**                                                          
   Yes                                                             1440      49.01
   No                                                              1498      50.99
  **Pre-op HCC**                                                             
   Yes                                                             1313      44.69
   No                                                              1625      55.31
  **Liver cirrhosis**                                              2484      84.55
  **Chronic hepatitis**                                                      
  Yes                                                              2761      93.98
   HBV-related                                                     1416      48.20
  HCV-related                                                      662       22.53
   Alcohol-related                                                 565       19.23
  No                                                               177       6.02
  **Biliary atresia**                                                        
   Yes                                                             284       9.67
   No                                                              2654      90.33
  **Wilson\'s disease**                                                      
   Yes                                                             35        1.19
   No                                                              2903      98.81
  **Glycogen storage disease**                                               
   Yes                                                             28        0.95
   No                                                              2910      99.05
  **Urea cycle metabolism disorders**                                        
   Yes                                                             16        0.54
   No                                                              2922      99.46

Values are mean and standard deviation. HCC, hepatocellular carcinoma.

Risk of post-transplant malignancies in the LTRs compared with the general Taiwanese population {#s3_2}
-----------------------------------------------------------------------------------------------

The annual incidences of malignancies for the estimated Taiwanese population of 23.32 million as of 2012 are listed in Table [2](#T2){ref-type="table"}. The average annual incidence of *de novo* malignancies from 1998 to 2012 was approximately 0.32% in the general population. In the LTRs, the proportion of total post-transplant malignancies was 9.67%, the proportion of *de novo* malignancies was 3.34% (98/2938), and that of recurrent malignancies was 6.33% (186/2938). Moreover, the standardized incidence ratio (SIR) of *de novo* cancer between LTRs and the general population was 2.17 (95% CI, 1.76 to 2.64).

###### Annual number of patients with de novo malignancy in cohort study and general Taiwan population from 1998 through 2012

  Year    General population   Cohort population                     
  ------- -------------------- ------------------- ---- ----- ------ -------
  1998    52207                21928591            0    0     12     180
  1999    56323                22092387            0    0     29     586
  2000    59116                22276672            0    0     40     1106
  2001    61606                22405568            0    0     64     1874
  2002    63736                22520776            0    3     70     2644
  2003    62542                22604550            4    2     134    3984
  2004    67895                22689122            9    8     108    4956
  2005    68907                22770383            3    7     158    6220
  2006    73293                22876527            8    7     179    7473
  2007    75769                22958360            5    16    227    8835
  2008    79818                23037031            8    12    289    10280
  2009    87189                23119772            13   25    326    11584
  2010    90649                23162123            16   41    406    12802
  2011    92682                23224912            14   46    478    13758
  2012    96694                23315822            18   19    418    14176
  Total   1088425                                  98   186   2938   

Incidence and mortality of post-transplant malignancies {#s3_3}
-------------------------------------------------------

Of the 2938 LTRs, 2795 were followed for more than 3 months postoperatively. 284 LTRs had post-transplant malignancies, including *de novo* or recurrent malignancies, while 2503 LTRs followed for more than 3 months postoperatively, were malignancy free throughout the study period. Eight other patients had the same well-controlled malignancies pre- and postoperatively (Figure [1](#F1){ref-type="fig"}). The 284 LTRs that developed post-transplant malignancies, included 99 *de novo* cancers among 98 recipients and recurrent cancers in 186 recipients. The characteristics of all postoperative malignancies are summarized in Table [3](#T3){ref-type="table"}. In *de novo* malignancies, the commonly affected organs or disease were the liver (19.39%), the oropharynx (19.39%; 6.12% of the oral cavity and 13.26% of the pharynx), non-Hodgkin\'s lymphoma (9.18%), the prostate (6.12%), and the esophagus (5.10%). Moreover, in recurrent malignancies, the commonly invaded organs were the liver (83.33%), lung (4.84%), bone and bone marrow (4.30%), and intrahepatic bile ducts (2.69%).

![Flowchart\
ICD-9-CM, International Classification of Disease, Ninth Revision, Clinical Modification; NHIRD, National Health Insurance Research Database.](oncotarget-07-83784-g001){#F1}

###### Type, incidence, and malignancy-free interval after liver transplantation

                                                                 Number   Malignancy-free interval (years)           
  -------------------------------------------------------------- -------- ---------------------------------- ------- -------
  ***De novo* malignancy (*N*= 98)**                                                                                 
  Oral cavity                                                    6        2.21                               0.66    6.41
  Pharynx                                                        13       2.17                               0.47    7.92
  Esophagus                                                      5        4.27                               1.12    5.71
  Stomach                                                        3        6.59                               2.25    6.66
  Small intestine                                                1        2.11                               2.11    2.11
  Colon                                                          2        1.54                               1.26    1.83
  Rectum                                                         2        2.21                               1.47    2.95
  Liver                                                          19       1.49                               0.55    5.45
  Ampulla of Vater                                               1        0.89                               0.89    0.89
  Gallbladder and extrahepatic bile ducts                        1        4.96                               4.96    4.96
  Pancreas                                                       1        3.95                               3.95    3.95
  Ill-defined sites within the digestive organs and peritoneum   1        14.08                              14.08   14.08
  Larynx                                                         2        4.95                               2.39    7.52
  Lung                                                           4        1.13                               0.56    8.99
  Pleura                                                         1        1.89                               1.89    1.89
  Connective tissue                                              1        1.05                               1.05    1.05
  Skin                                                           1        7.17                               7.17    7.17
  Breast                                                         4        1.55                               0.56    2.53
  Kaposi\'s sarcoma                                              2        0.89                               0.66    1.12
  Cervix uteri                                                   2        2.74                               1.39    4.08
  Prostate                                                       6        3.09                               0.85    9.47
  Bladder                                                        2        4.78                               3.04    6.52
  Kidney                                                         1        0.57                               0.57    0.57
  Brain                                                          3        1.27                               0.99    4.89
  Thyroid gland                                                  1        7.44                               7.44    7.44
  Non-Hodgkin\'s lymphoma                                        9        2.27                               0.58    4.90
  Hodgkin\'s disease                                             1        3.53                               3.53    3.53
  Lymphoid leukemia                                              2        2.74                               2.04    3.45
  Myeloid leukemia                                               2        1.36                               0.79    1.93
  Total                                                          99       2.11                               0.47    14.08
  **Recurrent malignancy (*N*= 186)**                                                                                
  Liver                                                          155      1.29                               0.56    9.58
  Intrahepatic bile ducts                                        5        2.15                               1.65    2.71
  lymph nodes                                                    3        1.10                               0.39    1.64
  Lung                                                           9        0.95                               0.62    8.33
  Pleura                                                         1        2.47                               2.47    2.47
  Peritoneum                                                     1        0.85                               0.85    0.85
  Other digestive organs and spleen                              1        1.08                               1.08    1.08
  Brain and spinal cord                                          2        1.11                               0.98    1.24
  Bone and bone marrow                                           8        1.07                               0.55    3.34
  Other specified sites                                          1        1.99                               1.99    1.99
  Total                                                          186      1.28                               0.39    9.58

The postoperative cumulative cancer probability examined using the Kaplan-Meier curve is presented in Figure [2](#F2){ref-type="fig"}. The cumulative cancer probability for LTRs at 1, 3, 5, and 10 postoperative years was 28.87% (82/284), 82.39% (234/284), 92.25% (262/284), and 99.65% (283/284), respectively. Furthermore, in *de novo* malignancies, the cumulative cancer probability at 1, 3, 5, and 10 postoperative years was 21.43% (21/98), 66.33% (65/98), 84.69% (83/98), and 98.98% (97/98), respectively. The mean time for the first diagnosis of postoperative cancer was 2.10 years (range, 0.39-14.28 years; median, 1.50). Recurrent malignancies developed faster than *de novo* malignancies. The cumulative cancer probability reached 90% at 2.91 years and 6.59 years in the recurrent and *de novo* malignancy groups, respectively.

![Cumulative cancer probability of de novo, recurrent, and all malignancies in the liver transplant recipients](oncotarget-07-83784-g002){#F2}

In this study, 88 patients with postoperative malignancies died, and their mean survival time from diagnosis was 6.07 ± 0.17 (mean ± SE) years. For all patients in this cohort there were 428 deaths, and the mean survival time from diagnosis was 9.78 ± 0.09 (mean ± SE) years. The mortality rates were significantly higher in the LTRs than in the general population in Taiwan (<http://www.ris.gov.tw/zh_TW/346>).

Risk factors associated with post-transplant malignancies {#s3_4}
---------------------------------------------------------

To analyze and compare the effects of specific risk factors, the LTRs were divided into two groups based on whether they had post-transplant malignancies in the cohort interval. Risk factors for each group are summarized in Table [4](#T4){ref-type="table"}. Older LTRs were more predisposed to post-transplant malignancies than younger ones (hazard ratio, 1.025; 95% CI, 1.016 to 1.033; *p* \< 0.0001). The risk of post-transplant malignancies was significantly higher in males than in females (hazard ratio, 1.51; 95% CI, 1.15 to 2.00; *p* = 0.0033). Patients with a past history of liver cirrhosis (hazard ratio, 1.46; 95% CI, 1.01 to 2.13; *p* = 0.0468) or chronic hepatitis (hazard ratio, 2.00; 95% CI, 1.06 to 3.77; *p* \< 0.0329) were predisposed to malignancies. LTRs with hepatitis B, but not hepatitis C or alcoholic hepatitis, had a significantly elevated risk of cancer (*p* = 0.0085, 0.062, and 0.6235, respectively). Furthermore, recipients with biliary atresia (hazard ratio, 0.28; 95% CI, 0.16 to 0.50; *p* \< 0.0001) or urea cycle metabolism disorders (*p* \< 0.0001) appeared to be protected from malignancies. Peptic ulcers (hazard ratio, 1.53; 95% CI, 1.21 to 1.94; *p* = 0.0004) and diabetes mellitus (hazard ratio, 1.36; 95% CI, 1.04 to 1.79; *p* = 0.0264) were significantly more common in the malignancy group than in the non-malignancy group. In our study, the risk of postoperative malignancies was significantly higher in the LTRs with preoperative malignancies (hazard ratio, 3.82; 95% CI, 2.94 to 4.96; *p* \< 0.0001). However, socioeconomic deprivation and other systemic diseases, such as hypertension, lung disease, or renal failure, were not associated with post-transplant malignancies. Postoperative sepsis, postoperative bleeding, epidural anesthesia, and morphine usage were not associated with postoperative malignancies.

###### Analysis of risk factors for post-transplant malignancy

                                            Without malignancy after transplantation (*N* = 2503)   With malignancy after transplantation (*N* = 284)   Hazard Ratio   (95% CI)   *p*-value                           
  ----------------------------------------- ------------------------------------------------------- --------------------------------------------------- -------------- ---------- ----------- ------------- --------- --
  Age[^†^](#tfn_002){ref-type="table-fn"}   45.90                                                   ±18.10                                              50.29          ±13.36     1.03        (1.02,1.03)   \<.0001   
  Gender                                                                                                                                                                                                              
   Male                                     1742                                                    69.60                                               219            77.11      1.51        (1.15,2.00)   0.0033    
   Female                                   761                                                     30.40                                               65             22.89      \-          \-            \-        
  Socioeconomic deprivation                                                                                                                                                                                           
   1(most deprived)                         886                                                     35.40                                               87             30.63      0.70        (0.35,1.40)   0.3113    
   2 (0-2.5k)                               965                                                     38.55                                               108            38.03      0.90        (0.45,1.79)   0.7628    
   3 (2.5k-5k)                              481                                                     19.22                                               64             22.54      1.07        (0.53,2.18)   0.8447    
   4 (5k-7.5k)                              105                                                     4.19                                                16             5.63       1.14        (0.50,2.59)   0.7608    
   5 (\>7.5k)                               66                                                      2.64                                                9              3.17       \-          \-            \-        
  Pre-operative cancer                      1159                                                    46.30                                               211            74.30      3.82        (2.94,4.96)   \<.0001   
  Liver cirrhosis                           2105                                                    84.10                                               253            89.08      1.46        (1.01,2.13)   0.0468    
  Ascites                                   1196                                                    47.78                                               134            47.18      0.85        (0.67,1.07)   0.1684    
  Chronic hepatitis                         2342                                                    93.57                                               274            96.48      2.00        (1.06,3.77)   0.0329    
  Hepatitis B                               1196                                                    47.78                                               156            54.93      1.37        (1.08,1.73)   0.0085    
  Hepatitis C                               557                                                     22.25                                               69             24.30      1.30        (0.99,1.70)   0.062     
  Alcoholic hepatitis                       482                                                     19.26                                               51             17.96      1.08        (0.80,1.46)   0.6235    
  Hepatic coma                              849                                                     33.92                                               93             32.75      0.92        (0.71,1.17)   0.4799    
  Hypertension                              505                                                     20.18                                               53             18.66      1.14        (0.85,1.54)   0.3852    
  Diabetes mellitus                         512                                                     20.46                                               67             23.59      1.36        (1.04,1.79)   0.0264    
  Peptic ulcer                              1193                                                    47.66                                               161            56.69      1.53        (1.21,1.94)   0.0004    
  Renal failure                             87                                                      3.48                                                13             4.58       1.35        (0.78,1.35)   0.2885    
  Pulmonary disease                         354                                                     14.14                                               44             15.49      1.23        (0.89,1.70)   0.2029    
  Hypercholesterolemia                      331                                                     13.22                                               26             9.15       0.80        (0.53,1.20)   0.2731    
  Biliary atresia                           272                                                     10.87                                               12             4.23       0.28        (0.16,0.50)   \<.0001   
  Wilson\'s disease                         34                                                      1.36                                                1              0.35       0.20        (0.20,1.35)   0.0979    
  Glycogen storage disease                  26                                                      1.04                                                1              0.35       0.25        (0.03,1.84)   0.1734    
  Urea cycle metabolism disorders           16                                                      0.64                                                0              0.00       0.00        (0.00,0.00)   \<.0001   
  Obese                                     10                                                      0.40                                                2              0.70       1.91        (0.50,7.39)   0.3466    
  Bacteremia                                137                                                     5.47                                                12             4.23       0.60        (0.34,1.09)   0.0926    
  Postoperative bleeding                    126                                                     5.03                                                21             7.39       1.16        (0.74,1.81)   0.5245    
  Epidural anesthesia                       11                                                      0.44                                                1              0.35       0.62        (0.09,4.39)   0.6290    
  Morphine                                  1246                                                    49.78                                               137            48.24      0.81        (0.65,1.03)   0.0797    

Values are mean and standard deviation.

Hazard ratios are for malignancy as compared with non-malignancy after transplantation. CI denotes confidence interval.

Recurrent malignancies considerably increased mortality in the LTRs {#s3_5}
-------------------------------------------------------------------

The results revealed increased mortality in the LTRs with postoperative malignancies, and the LTRs with recurrent malignancies had higher mortality than did those with no postoperative malignancies (RR = 3.15, CI = 2.49 to 4.00) or with *de novo* malignancies (RR = 1.13, CI = 0.78 to 1.64), respectively. The result suggested that compared with the de novo or postoperative cancer-free groups, the recurrent group considerably increased LTR mortality (Figure [3](#F3){ref-type="fig"}).
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Overall mortality among the four groups were 5.13% (143/2787), 9.36% (261/2787), and 11.12% (310/2787) at 1, 3, and 5 years, respectively. The mortality rates of the *de novo* group were 9.52% (2/21), 12.31% (8/65), and 26.51% (22/83) at 1, 3, and 5 years, respectively. Furthermore, in the recurrent group, the mortality rates were 8.20% (5/61), 24.85% (42/169), and 30.17% (54/179) at 1, 3, and 5 years, respectively. Moreover, the 10-year patient mortality rates in the malignancy-free, malignancy-cured, *de novo*, and recurrent groups were 8.10% (109/1345), 12.60% (146/1159), 28.87% (28/97) and 32.26% (60/186), respectively. These results indicated a strong association of mortality with postoperative malignancies; the LTRs with postoperative malignancies revealed higher mortality, particularly considering those with recurrent malignancies.

DISCUSSION {#s4}
==========

In this retrospective study of 2938 LTRs, *de novo* malignancies occurred in 3.34% of recipients at a mean relapse time of 5.71 years postoperatively. The recurrence rate among the patients with pre-existing malignancies was 12.92% (186/1440) at a mean elapsed time of 1.71 years. Moreover, the SIR of postoperative *de novo* cancers was 2.17-fold (95% CI, 1.76 to 2.64) compared to the general Taiwanese population. Our data are consistent with those of previous studies that reported the tendency to develop malignancies after solid organ transplantation, in which the relative risk ratio was estimated to be between 2.1 and 4.3 \[[@R5], [@R7]--[@R9]\].

Our present study revealed that 65.49% (186/284) of post-transplant malignancies were recurrent. The most common relapse site was the liver, and distal metastasis occurred at the lung and bone or bone marrow. The most common *de novo* malignancies in the LTRs were HCC (SIR: 3.15, CI: 1.90-4.92), oropharyngeal cancer (SIR: 4.61, CI: 2.77-7.19), and non-Hodgkin\'s lymphoma (SIR: 8.42, CI: 3.84-15.98), which were all confirmed as infection-related malignancies. The results differed from the prevalence of cancer types in Taiwanese population, in whom the most common malignancies were observed at the colon or rectum, liver, lung, and breast, in that order. Iatrogenic immunosuppression is associated with oncogenesis and immune deficient patients with AIDS also showed significantly higher SIRs for infection-related malignancies than the general population. HCC is associated with hepatitis B and C virus infection; oropharyngeal cancer is HPV related; and non-Hodgkin lymphoma is Epstein-Barr virus related \[[@R10]\]. In addition, esophageal and gastric cancers were *Helicobacter pylori* related \[[@R10], [@R17]\], and comprised 8.25% of *de novo* malignancies observed in LTRs. Multivariate analysis also revealed that post-transplant malignancies were significantly associated with hepatitis B, but not with hepatitis C or alcoholic hepatitis. Preoperative hepatitis virus B-infected patients appeared predisposed to oncogenesis after immunosuppression. Furthermore, *H. pylori* infection is a major risk factor for peptic ulcers, infecting 90%-100% and 60%-90% of patients with gastric and duodenal ulcers, respectively \[[@R18], [@R19]\]. We could not directly evaluate *H. pylori* infection in the LTRs; however, we observed an association between patients with peptic ulcers and malignancies. Vigorously treating peptic ulcers before administering immunosuppressant might reduce post-transplant malignancies, particularly esophageal and gastric cancers; however, further studies are required to support this hypothesis. In conclusion, our results reveal the effect of immunosuppressive treatment on postoperative malignancies in LTRs. A similar risk of cancer in the LTRs and patients with AIDS suggests that immune deficiency is, at least partially, responsible for the increased risk.

In this study of the Chinese ethnicity, skin cancer was relatively rare, estimated to be 1.01% in the *de novo* group; however, it is relatively common in *de novo* malignancies reported in western countries \[[@R20]\]. Skin cancer accounted for 38.67% of postoperative malignancies in a similar study of the Swedish population \[[@R20]\]. Among post-transplant *de novo* malignancies, 5.3% of American recipients and 4.21% of Australian recipients reported malignancies among solid organs, including the liver, kidneys, heart, and lungs \[[@R8], [@R21]\]. Furthermore, the postoperative melanoma incidence has been reported as 2%-4% in Swedish and Italian populations \[[@R9], [@R20]\]; however, no melanoma developed in our cohort.

Age and sex were the major risk factors for post-transplant malignancies, thus warranting detailed screening for malignancies. Patients with comorbidities of preoperative liver cirrhosis, diabetes mellitus, and pre-existing cancers were also high-risk populations. Advanced liver fibrosis is a confirmed risk factor for HCC carcinogenesis \[[@R22]\]. Pre-existing malignancies are recurrent in nature, and this factor may be apparent under the effect of tumor surveillance escape as natural killer cells are inhibited by immunosuppressant. Patients with biliary atresia or urea cycle metabolism disorders appear to have a decreased risk of post-transplant cancers. These findings should not be inclusion or exclusion criteria for liver transplant candidates; instead, they must remind clinicians to reduce the immunosuppressant dose and to carefully screen for risk.

A low socioeconomic status is correlated with the incidence and mortality of various malignancies, such as HCC, esophageal, breast, and colorectal cancer \[[@R23]--[@R28]\]. Our present data revealed no correlation between socioeconomic status and incidence of post-transplant malignancies (*p* = 0.3312). This may have contributed to earlier diagnosis and optimal treatment without the barriers of socioeconomic status because of the patient care provided by the NHI program. This observation was also supported by the relatively lower SIR (2.17-fold) of de novo cancer in our cohort compared with that reported by previous studies (2.1 to 4.3-fold). Iwasaki et al. reported the possible influence of volatile anesthetics on cancer cell biology and metastatic potential *in vitro* study \[[@R29]\]. However, NHIRD cannot provide any record of anesthetic used in surgery.

The recipients with post-transplant malignancies had a significantly higher mortality; those with recurrent malignancies survived less frequently than those with de novo malignancies. Our data revealed that the mortality of malignancy-cured patients was slightly inferior to that of malignancy-free patients, but lower than that of the *de novo* and recurrent groups. The 10-year patient mortality rates were 8.1% and 12.6% in the malignancy-free and malignancy-cured groups, supporting the assumption that liver transplantation is a favorable treatment option for localized HCC with no recurrence. Moreover, careful patient selection and an immunosuppression-minimizing strategy are warranted.

The study has some limitations. First, the NHIRD could not provide data on risk factors, such as lifestyle, living or working environment, and family history \[[@R30]\]. Smoking, alcohol consumption, environmental toxins or pollution, and genetic inheritance play crucial roles in oncogenesis. The effects of latency and dosage on these risk factors were also unknown. In addition, the average follow-up interval was relatively short (3.79 ± 3.26 years) and may cause the underestimation of late-onset carcinogenesis. Second, although the present study revealed risk factors for post-transplant malignancies, the actual causality between them remains unconfirmed. Third, in addition to immunosuppressant-induced malignancy, circulating cancer cells before transplantation, surgical manipulation-induced tumor seeding, and tumorigenesis tendency of recipients were possible risk factors for recurrence of post-transplant HCC unaccounted for in our data.

Our study analyzed data from the NHIRD, which was provided by the Bureau of National Health Insurance, Department of Health and is governed by the National Health Research Institutes. Interpretation and conclusions reported herein do not represent the views of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes.
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